BAYRY
Staying power, not just a placeholder
Bayer’s board just decided Bill Anderson gets to keep driving the bus a little longer. His contract has been extended by three years, all the way to 31 March 2029, which is board-speak for: we’re not swapping out the pilot mid-flight.
Why the board is cheering
Chairman Norbert Winkeljohann said the company is starting to see “clear successes,” even though there’s still plenty of mess to clean up. That matters because Bayer has spent the last couple of years trying to untangle its post-acquisition headache pile while steering the business back toward growth.
The company is pointing to a few brighter spots in the portfolio:
- Kerendia for chronic kidney disease and heart failure
- Nubeqa in prostate cancer
- Beyonttra with partner BridgeBio in ATTR-CM
- Lynkuet, a newly approved menopause therapy
The long game is still long
Anderson says 2025 will be the toughest year of the restructuring, with a return to growth expected in 2026. Translation: this is still a marathon, not a victory lap. But when a board extends the CEO’s deal this early, it usually means it thinks the plan is working well enough to avoid a leadership soap opera.
Big picture
Bayer’s stock has already bounced a bit in 2025 after flirting with two-decade lows in 2024. This contract extension won’t fix the whole story, but it does suggest the board wants continuity while the turnaround tries to go from “painful” to “maybe, eventually, profitable.”